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ABSTRACT 
!
BACKGROUND: An understanding of the relationship between patient factors and healthcare 
resource utilization represents a major point of interest for optimizing clinical care and overall 
net savings, yet maintaining financial margins for provider revenues. This study aims to review 
resource utilization after cholecystectomy in order to characterize patient factors associated with 
increased postoperative ED visits and 30-day readmissions. 
METHODS: 53,632 open and laparoscopic cholecystectomies were reviewed from July-2009 to 
December-2010 in a large private payer claims database. ICD-9 and CPT codes were available 
for each event, as well as basic demographics. Data regarding 30-day postoperative resource 
utilization metrics (emergency department visits and inpatient hospitalizations) were analyzed 
and stratified by key patient comorbidities. Differences between subgroups were evaluated with 
univariate and multivariable methods. 
RESULTS: Of the 53,632 patients studied, 71.2% (38,171) were female and 28.8% (15,461) male.  
Resource utilization within 30-days of surgery included: 6.6% (3,538) of patients with an ED 
visit and 7.7% (4,103) with an inpatient hospitalization. The most common comorbidities in the 
study population were: hypertension, hyperlipidemia, GERD / hiatal hernia, and diabetes 
mellitus. Patients with heart failure, cirrhosis, and a history of MI or acute ischemic heart disease 
all had a significant association with postoperative ED visit and the highest likelihood of 
inpatient hospitalization. Angina, diabetes, and hypertension similarly increased both ED 
utilization and inpatient readmissions to a lesser but still significant extent. Although patients 
with GERD / hiatal hernia and sleep apnea had a significant association with ED use, they did 
not have an increased likelihood of readmission. 
CONCLUSIONS: Patient comorbidity indexing plays a major role in clinical risk stratification and 
resource utilization for cholecystectomy. These factors should be considered in bundled 
reimbursement packages and in the creation of preventive postoperative ambulatory strategies 
given their role in determining potential resource utilization in the postoperative setting. 
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GLOSSARY 
!
ACA Affordable Care Act 
ACO Accountable care organizations 
BPCI Bundled Payments for Care Improvement 
CCTP Community-based Care Transitions Program 
CMS Centers for Medicare & Medicaid Services 
CPT Current Procedural Terminology 
ED Emergency department 
GDP Gross domestic product 
GERD Gastroesophageal reflux disease 
HIV/AIDS Human immunodeficiency virus / Acquired immunodeficiency syndrome 
ICD-9 International Classification of Diseases, Ninth Revision 
IHD Ischemic heart disease 
IRB Institutional review board 
JSH Joint replacement surgical home 
LOS Length of stay 
MI Myocardial infarction 
MS-DRG Medicare Severity Diagnosis Related Group 
NOS Not otherwise specified 
OECD Organisation for Economic Co-operation and Development 
OR Odds ratio 
RUQ Right upper quadrant 
THA Total hip arthroplasty 
TKA Total knee arthroplasty 
UC University of California 
VNA Visiting Nurse Association 
VBP Hospital Value-Based Purchasing Program 
WWII World War II 
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INTRODUCTION 
!
BACKGROUND: THE US OUTLIER AND THE AFFORDABLE CARE ACT 
In mid-2007, the United States began to slip into the start of what was to become the 
worst financial crisis in the post World War II (WWII) era1; it was informally referred to as the 
Great Recession. The US gross domestic product (GDP) dropped a staggering 5.1% during the 
worst of it, from the fourth quarter of 2007 through the second quarter of 2009. Prior to this, the 
largest recorded drop in the post-WWII era had been just 3.7% in 1957-19582. Unemployment 
figures skyrocketed reflecting the 8.7-million jobs lost. Consumer spending and business 
investments plummeted as the US economy headed towards its worst nadir in modern history2,3. 
Despite the recession and accompanying period of sluggish economic recovery through 
2013, the United States spent an estimated $2-3 trillion per year on health care, with 
expenditures rising annually. Through 2013, health care comprised an impressive 17.4% of the 
United States GDP4,5. This figure corroborates that the US spent more of its GDP on health care 
than any other country in the world. As evident in Figure 1 from Schoen et al6, the US devoted a 
6% greater share of its economy on health than the Netherlands, the country with the second 
largest proportion of its GDP spent on health care. 
Were health accessibility, affordability, and outcomes similar between the US and the 
other countries listed above, perhaps this number would not be so troubling; existing data, 
however, show that these exorbitant costs did not and still do not translate to better care. 
 
Accessibility 
Before the implementation of the Patient Protection and Affordable Care Act (ACA), 
16% of the entire US population – consisting of approximately 50-million people – were 
completely uninsured. Moreover, millions of Americans remained underinsured, meaning 
they lost a significant portion of their income to health care costs not covered by 
insurance6,7. In some states such as Nevada and Texas, the percentage of uninsured 
soared at an incredible 27% of the adult population8. This remains a stark contrast to the 
universal health coverage provided by our western counterparts in Europe, where the 
J.Boehme!
7 
 
percentage of uninsured is virtually 0%. Figure 2 from the Organisation for Economic 
Co-operation and Development (OECD)’s health indicators9 depicts the percentages of 
the population that were either insured (via public or private insurance) or uninsured 
across the various OECD participating countries in 2007. 
 
Affordability 
In the Schoen et al study6 previously mentioned that included ten of the world’s major 
developed nations in addition to the US, adults in the US were more likely than adults in 
any other nation to have healthcare access issues related to cost. For example, they were 
the most likely to have not seen a doctor when ill or not get recommended care due to 
cost. They also did not fill their prescription medications and skipped medication doses 
2.6 times as often as adults in the country second most likely to have done so, Canada. 
Finally, adults in the United States were more likely than adults in all other countries to 
have had $1,000 or more out-of-pocket medical expenditures. 
 
Health Outcomes 
Life expectancy and child mortality: In 2007, life expectancy at birth in the US (78.1 
years) was one year less than the OECD average (79.1 years) and approximately two 
years less than that of any western European nation. Although life expectancy in the US 
(78.8 years) increased slightly in 2013, it staggered and lingered almost one year behind 
the OECD average (80.5 years) and 2-4 years behind the life expectancy in western 
European nations9,10. 
Low birth weight: The US had one of the incidence levels of low birth weight infants in 
2007, with 8.3% of infants born weighing less than 2,500g; the OECD average at the time 
was 6.8% of infants. Both incidence levels decreased in 2013, with the US at 8.0% of 
infants weighing less than 2,500g at birth and the OECD average at 6.6% of infants9,10. 
Prevalence and incidence of various illnesses: The estimated prevalence of diabetes in the 
US (10.3%) ranked only second to Mexico (10.8%) in 2010, and led the OECD average 
J.Boehme!
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(6.3%) by a full four percentage points. In 2006, the incidence of HIV/AIDS was highest 
in the US of all the OECD countries, at a stunning 127 new cases per million in the 
general population; OECD average was almost eight times less, at 16.2 new cases per 
million9,10. 
Mortality due to various illnesses: As compared to other western European nations, the 
US ranks highly in terms of death as a result of ischemic heart disease (IHD) although 
this number has decreased since 2006. Mortality rates due to all cancers and 
cerebrovascular disease were appreciably lower in the US than in other western nations in 
both the OECD’s 2009 and 2015 reports9,10. 
 
Defining Value 
Figure 3 depicts the relationship between life expectancy and total health spending per 
person11. The United States is shown on the far right-bottom with a high cost and low life 
expectancy, relative to the other countries shown. Similarly, Figure 4 demonstrates the 
association between child mortality and total health spending per person11. The US is 
shown on the far right-top with a high cost and high child mortality. Michael Porter from 
Harvard Business School defined value within health care delivery as the health 
outcomes achieved per dollar spent12. Given the low life expectancy and high child 
mortality rates despite the elevated cost of care, these data indicate that the value of 
health care in the US is inferior to that of much of the developed world. 
 
In order to begin to address these overwhelming issues of poor access to health, 
inadequate insurance coverage, unsustainable costs, and the inferior value of health care in the 
US, the ACA was implemented in 201013. The ACA created the structural foundation for 
interventions intended to increase insurability and contain healthcare costs. Examples of cost-
containment programs included in the act were Community-based Care Transitions Program 
(CCTP) to decrease readmission rates, Hospital Value-Based Purchasing Program (VBP) to shift 
financial risk from Medicare to providers in order to transform incentives, and the Shared 
Savings Program to reward providers for reducing costs7. The scaffolding that the ACA provided 
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laid the groundwork for the establishment of accountable care organizations (ACOs) and the 
widespread use of bundled payments. In 2011, the Centers for Medicare & Medicaid Services 
(CMS) launched the Bundled Payments for Care Improvement (BPCI) initiative in accordance 
with Section 3023 of the ACA; this stated that Medicare bundled payments would be piloted in 
2013. CMS commenced the application of cost savings paradigms via bundled payments when it 
announced the healthcare organizations selected to participate as ACOs in the BPCI in January 
of 201314. Through these approaches, implementation of the ACA has slowly initiated a 
transformation in economic incentives that increase provider participation in order to achieve its 
goals of creating high value, affordable health care available to most15. Thus, the ACA triggered 
a closer look at healthcare spending with the aim to decrease inefficiencies, increase the quality 
of care that patients receive, and lower overall healthcare costs. 
 
RISK STRATIFICATION OF BUNDLED PAYMENTS 
In order to account for fluctuations in costs per patient, the ACA called for a risk 
adjustment strategy. Accordingly, bundled payments in the ACA and BPCI initiative were 
founded in risk stratification based on the existing Medicare Severity Diagnosis Related Group 
(MS-DRG). The MS-DRG attaches significance to acute illnesses or acute decompensations of 
chronic illnesses16. Thence, bundled payments to ACOs were to include increased payments 
based on MS-DRG risk stratification to to compensate for the higher costs of treating more 
severely ill patients. 
The higher cost of treating sicker patients does not solely correlate with the acute disease 
burden represented by the MS-DRG, however; chronic disease burden significantly impacts a 
patient’s total cost of care and may in fact play a greater role in resource utilization than acute 
disease burden does. Vertrees et al found that a patient’s chronic disease burden may in fact be 
more predictive of a patient’s resource use than the acute disease burden16. Hughes et al showed 
the predictive power of integrating the chronic disease burden of patient comorbidities into a 
system of risk categories in order to stratify patients by their expected use of healthcare resources 
in a future year17. Therefore, although existing risk adjustment under the ACA was founded in 
the known effects of acute illness, chronic disease burden may also prove a significant target. 
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CASE: THE CHOLECYSTECTOMY AND CONTRIBUTORS TO RESOURCE USE 
Gallstone disease is the fourth most costly gastrointestinal disease in the United States; 
direct and indirect costs for care related to cholelithiasis totaled $6.2-billion in 200418. Not 
surprisingly, the cholecystectomy is the most common elective abdominal surgical procedure 
performed in the United States with more than 750,000 cases occurring each year19. Considering 
the factors that contribute to the estimated $15,651 median cost per case20, complications and 
comorbidities may play a significant role in the total cost of care. Injury to the common bile duct 
is well known as a major contributor to cost and resource utilization, with immediate associated 
costs ranging from $13,612 to $30,000 and lifetime costs reported as high as $300,00021–24. In 
addition, various patient, hospital, and surgeon factors – such as age, sex, presence of 
comorbidities, urgency of admission and surgery, length of stay (LOS), treatment in a regional or 
district hospital, hospital volume, and surgeon experience25–32 – have been shown to affect 
cholecystectomy outcomes and associated overall resource use and costs. 
As previously mentioned, chronic disease burden has been shown to be more predictive 
of patient cost and resource use than acute illness16,17. Prior studies have also evinced the 
influence of patient comorbidities on the utilization of resources such as office visits, emergency 
department (ED) visits, length of stay, drug costs, procedures, and overall costs in other study 
populations33–37. 
Given the significance of chronic illness burden and the knowledge of how patient factors 
influence resource utilization in other conditions, this study serves to elucidate the impact of 
specific patient comorbidities on resource utilization after cholecystectomy. In the context of our 
current healthcare system’s movement towards innovative reimbursement models, quantification 
of these impacts may be useful to payers for guiding the development of risk-stratified, case-mix 
appropriate bundled reimbursement packages to providers for cholecystectomies. Furthermore, 
this information may be useful to providers in order to create strategies to prevent excess 
resource utilization, thereby decreasing inefficiencies, increasing the value of care for patients, 
and simultaneously creating profit margins under the ACA’s Shared Savings Program. 
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METHODS 
!
This was a retrospective observational cohort study of privately insured patients 
undergoing cholecystectomy in which predictor variables were defined by the presence or 
absence of various chronic comorbid conditions. Approval from the Cambridge Health Alliance 
institutional review board (IRB) was obtained. 
 
STUDY DESIGN 
This study was a retrospective cohort study utilizing a private payer claims database 
(Aetna, Inc., Hartford, CT). Inclusion criteria consisted of age !16 years, a record of 
cholecystectomy between July 1, 2009 and December 31, 2010, and enrollment in the health plan 
for at least 6 months before and 3 months after the cholecystectomy to stabilize the co-morbidity 
database and allow tracking of consecutive health events and resource use. Claims records were 
stripped of protected health information by Aetna personnel not involved in this study to produce 
the HIPAA-compliant de-identified dataset used in this analysis. Cholecystectomy procedures 
were identified by the International Classification of Diseases, Ninth Revision (ICD-9) or 
Current Procedural Terminology (CPT) codes listed in the appendix. 
 
OUTCOME MEASURES 
Data regarding 30-day postoperative resource utilization were stratified and analyzed by 
patient comorbidities. The comorbid conditions that were studied include hypertension, 
hyperlipidemia, gastroesophageal reflux disease (GERD) / hiatal hernia, diabetes mellitus, 
angina / chronic IHD, sleep apnea, heart failure, myocardial infarction (MI) / acute IHD, 
hypertensive heart disease, and cirrhosis of the liver or bile ducts. These conditions were defined 
by the presence of an associated ICD-9 code within the 6-month period immediately prior to the 
cholecystectomy.  
The endpoints in this study were 30-day ED visits, 30-day readmissions, and length of 
stay for the 30-day readmissions. A readmission was defined as utilization classified as inpatient 
in the source data. Length of stay was calculated as discharge date minus admission date. 
J.Boehme!
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STATISTICAL ANALYSES 
Descriptive statistics were used to summarize baseline patient characteristics, including 
demographics and comorbid conditions. Outcomes were summarized for the overall population 
and by subgroups with and without each comorbid condition. Pearson’s chi-squared p-values 
were calculated to evaluate the statistical significance of all differences in outcomes between 
cohorts. No adjustments were made to these p-values to account for multiple comparisons.  
Logistic regression was utilized to determine the impact of baseline comorbid conditions 
on 30-day readmission rates, while adjusting for demographic differences. Stepwise selection 
was used to choose the statistically significant predictor variables from among all studied 
comorbid conditions, age, gender, and region. Sensitivity regression models were also run for the 
subsets of readmissions including and not including an overnight stay. All statistical analyses 
were conducted using SAS Version 9.2 (SAS Institute, Cary, North Carolina). 
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RESULTS 
!
A total of 53,632 patients was included in this study; 71.2% (38,171) were female, 28.8% 
(15,461) male. Baseline patient characteristics are shown in Table 1. Of all cholecystectomies 
studied, 94.9% (50,900) were laparoscopic, 63.9% (34,285) were outpatient procedures, and 
51.2% (27,439) occurred in the South (US Census Region 3) of the United States. The 
prevalence of chronic comorbidities seen in the study population are reported in Table 2. 
Hypertension, hyperlipidemia, GERD / hiatal hernia, and diabetes mellitus were the most 
prevalent of the comorbid conditions studied, at 34.2% (18,324), 30.7% (16,436), 25.1% 
(13,465), and 13.7% (7,354) in the study population, respectively. 
Within 30-days of surgery, 6.6% (3,538) of patients returned to the ED a total of 4,523 
times. This led to an average of 1.3 ED visits per patient visiting the ED and an average of 0.1 
ED visits for the entire cohort. Additionally, 7.7% (4,103) of patients had inpatient readmissions 
within 30-days of their procedure. Of all patients with 30-day inpatient readmissions, 60.0% 
(2,461) had a LOS of 0 days,, 16.5% (677) 1-2 days, 14.2% (583) 3-5 days, 5.2% (214) 6-10 
days, and 4.1% (168) 11 days or longer. (Table 3) The top three diagnoses recorded during the 
inpatient readmissions were abdominal pain at an unspecified site, chest pain not otherwise 
specified (NOS), and abdominal pain in the right upper quadrant (RUQ) at 7.6% (700), 2.4% 
(223), and 2.4% (217), respectively (Table 4). 
ED visits were not significantly different across sexes but inpatient hospitalizations were, 
with males comprising a greater proportion of readmitted patients (9.9% males versus 6.8% 
females, p<0.0001) (Table 5). Resource utilization within 30-days of cholecystectomy, stratified 
by comorbid conditions, is shown in Table 6. All of the comorbidities studied, except for 
hyperlipidemia and hypertensive heart disease, had a significantly increased postoperative ED 
utilization. 
Odds ratios and 95% Wald confidence limits for the effect of baseline comorbidities on 
30-day readmission are shown in Table 7. All studied comorbid conditions except GERD and 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
,!Lengths of stay were calculated by subtracting discharge date from admission date. LOS of 0-days informs that the 
admission and discharge date were the same, suggesting discharge from the hospital before midnight on the same 
day as admission. 
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sleep apnea were statistically significant predictors of 30-day readmission. Of the remaining 
baseline comorbidities, all resulted in increased risk of readmission except for hyperlipidemia, 
which showed a slightly reduced risk after adjusting for all other predictors [Odds Ratio 
(OR)=0.867, CI: 0.801-0.938, p=0.0004]. Comorbid conditions that significantly increased the 
odds of a 30-day readmission included both acute and chronic IHD, cirrhosis of the liver or bile 
ducts, diabetes, heart failure, hypertension, and hypertensive heart disease. Age also had a highly 
significant impact on 30-day readmission, with OR estimates increasing from 0.993 for ages 35-
44 to 4.277 for ages 75 and older. Gender and region had modest but statistically significant 
impacts on 30-day readmission, with females at lower risk than males and patients in the South 
having the lowest regional risk compared to patients in the Midwest with the highest risk of 
readmission. 
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DISCUSSION 
!
INTERPRETATION OF RESULTS 
The relationship between chronic patient comorbidities and postoperative resource use 
after cholecystectomy has been poorly defined in the literature. Some reports relating 
comorbidities and/or complications to cost exist20,21,25,26, but a greater understanding of chronic 
disease burden on the utilization of specific resources is needed to guide both economic policy 
and clinical decision-making. This paper is intended to define the relationship that exists between 
patient comorbidities and postoperative utilization of resources in terms of distinct visits after 
laparoscopic and open cholecystectomy. 
In this study, patients with heart failure were the most likely of all to visit to the ED and 
to be readmitted; in fact, these patients are 2.1 times more likely than healthy patients to be 
readmitted within 30-days of their cholecystectomy. Patients with either cirrhosis or a history of 
acute IHD also had significant association with postoperative ED visit and were 1.5-1.6 times as 
likely to have an inpatient readmission. Those with chronic IHD, diabetes mellitus, and 
hypertension had a significant association with ED visit and also had a modestly increased 
likelihood of inpatient readmission that was 1.2-1.3 times that of their healthy counterparts. 
Forty-six percent of cholecystectomy costs are attributable to room and board20. 
Therefore, it is prudent to note the influence of the comorbidities that increase readmission rates 
and inpatient LOS after cholecystectomy in addition to those that increase ED utilization. 
Hyperlipidemia did not increase ED utilization and was a negative predictor of inpatient 
readmissions in this study population. This may reflect a population of otherwise healthy patients 
presenting with a ‘laboratory comorbidity’ as defined by strict numbers yet without any type of 
actual visceral organ disease. 
These data demonstrate how two patients with similar costs but different chronic 
conditions lead to different utilization of resources after surgery: a patient with GERD who visits 
the ED repeatedly for reflux symptoms and pain in the postoperative setting versus a patient with 
cirrhosis and heart failure requiring a prolonged inpatient hospitalization postoperatively due to 
fluid shifts and heart failure exacerbation after intraoperative fluid resuscitation. Although these 
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patients may be very similar in a strictly monetary sense, their use of hospital resources is vastly 
different. These insights will prove extremely valuable for applying paradigms for care 
coordination and cost savings under the ACA. 
 
RELEVANCE TO PAYERS 
An understanding of the specifics of resource utilization by patient comorbidity will first 
allow for appropriate departmental reimbursements by insurance companies. In this analysis, not 
every comorbidity that increased utilization of ED resources led to increased readmission rates. 
The two comorbidities that were associated with an increased likelihood of ED visit that did not 
lead to inpatient readmissions were GERD / hiatal hernia and sleep apnea. Similarly, the impact 
of resource use will vary from organization to organization based upon the characteristics of their 
patient population. 
Second, an understanding of the impact of each comorbidity from this paper can form the 
foundation for the risk adjustment of bundled payments for cholecystectomies based on a 
particular healthcare system’s chronic illness trends in their patient population. Calculations for 
bundled payments would be based on the likelihood of the various types of visits and LOS for 
inpatient readmissions. 
 
RELEVANCE TO PROVIDERS AND HOSPITAL ADMINISTRATORS 
Past successes in bundled payment models exist, a prime example of which is Geisinger 
Health System’s ProvenCare initiative for coronary artery bypass grafting38. However, 
reimbursements for surgical procedures are decreasing in the face of increasing productivity and 
governmental regulations. Over the past 15 years, reimbursement has decreased by 2.9% for 
cholecystectomies39. At present-day Medicaid reimbursement rates, Frazee et al’s analysis40 
defines the ‘break-even point’ for laparoscopic cholecystectomy at 454 cases - this presents a 
major financial limitation to lower-volume centers performing this operation and therefore may 
negatively impact access to care. Analysis of the comorbid conditions in a particular healthcare 
group’s coverage will aid in the projection of resource utilization and subsequent administrative 
planning for cholecystectomy. Such preparation will enable various processes: Opportunities for 
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the creation of preventive strategies, optimization of healthcare delivery, and appropriate 
distribution of reimbursement profiles to enable increased profit margins for providers, in the 
context of the risk-adjusted reimbursements from payers mentioned above. 
From the clinician perspective, the knowledge gained from this study will be used to 
guide strategies to optimize patients in the perioperative period and consequently, decrease 
postoperative resource utilization. Strategically preventing exacerbation of existing patient 
comorbidities in the perioperative setting represents one of the major goals of the BPCI and is 
currently a hot topic in the surgical care realm. To undertake this daunting task, administrators, 
physicians, and ancillary staff have come together in the few years since the implementation of 
the ACA to create the perioperative surgical home (PSH) model of care41. 
A mélange of evidence-based practices from lean six sigma theory and its predecessor, 
Enhanced Recovery After Surgery (ERAS)41, the PSH model of care has already been shown to 
minimize postoperative resource utilization and costs. In 2012, University of California (UC) 
Irvine implemented the patient-centered and physician-driven PSH model of care when it 
initiated its total knee arthroplasty (TKA) and total hip arthroplasty (THA) programs; a follow-
up study in two years after the commencement of both programs compared its costs to those in 
the reported literature. Costs for UC Irvine’s TKAs were, on average, $6,000-$8,000 less than 
the benchmark comparison42 and its THAs were approximately $5,000-$8,000 less43. 
Under the PSH model of care, interventions are targeted at various levels of patient care – 
the preoperative, intraoperative, and postoperative periods41. Innovative examples of cost saving 
strategies specific to patient comorbidities at each level of care might include the following. 
 
Preoperative Period 
Physicians could coordinate close follow-up in the 1-2 weeks prior to surgery for patients 
most likely to be readmitted. Such care could include weekly in-office visits or frequent 
phone calls with ancillary medical staff for careful titration of medications aimed at 
optimizing the patient’s physiologic balance before surgery. 
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Intraoperative Period 
During the intraoperative period, anesthesiologists must maintain equilibrium despite 
often opposing physiologic and surgical needs, with the added burden of chronic illness. 
If a patient is afflicted with a comorbid condition that significantly increases their 
likelihood of readmission such as heart failure in this study’s dataset, the anesthesiologist 
could consider immediate preoperative evaluation in the holding area with a bedside 
pulmonary and/or transthoracic ultrasound. This cheap and quick bedside examination 
could provide valuable information regarding the patient’s cardiac function and overall 
volume status via the presence of pathology such as pulmonary edema, pleural effusions, 
and inferior vena cava variability44. The anesthesiologist could then use this information 
to guide a restrictive or liberal volume resuscitation protocol intraoperatively, depending 
on other surgical factors as well. 
 
Postoperative Period 
In addition to the existing foundations for surgical recovery laid out by ERAS, clinicians 
could coordinate close follow-up care targeted at preventing exacerbations of chronic 
conditions for the patients statistically most likely to return to the hospital based on their 
disease states. Perioperative care physicians could coordinate follow-up telephone calls, 
home ambulatory services such as Visiting Nurse Association (VNA) visits, and 
outpatient follow-up with primary care providers. Without the added assurance of in-
house hospital monitoring, the postoperative period provides a unique environment in 
which the use of innovative technology could have great potential. Mobile health 
technologies could be provided to the highest-risk patients for real-time monitoring by 
third-party agencies and reporting to ancillary staff for health optimization. This novel 
application of technology could prevent chronic health exacerbations at the first sign of 
pathology, before symptoms ever developed and well before patients visited the ED or 
were readmitted. Devices could include smart watches for heart rate monitoring, at-home 
scales and sphygmomanometers with real-time data transmission, and more. 
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These services could not only lead to less ED visits and inpatient hospitalizations, but 
also result in better coordination of care, create greater value of services received for patients, 
and yield lower overall costs to the healthcare system. Although a study using aggregates of 
comorbidity information could have led to similar findings in terms of identifying trends in 
resource utilization with increasing chronic disease burden, aggregate patient data would not 
have allowed for the specific information provided by this study’s data to create targeted 
prevention strategies for individual comorbidities. 
The knowledge gained from this study can be used to: (1) Influence payers to create 
evidence-based payment models with global reimbursements focused on clearly defined 
packages of patient-centered and risk-stratified post-discharge resources in the postoperative 
setting after cholecystectomy; and (2) Guide providers to create targeted cost saving 
interventions in the pre-, intra-, and post- operative periods aimed at decreasing resource 
utilization for patients in the highest risk groups. 
 
SUGGESTIONS FOR FUTURE WORK 
Although the prevention strategies mentioned are certainly possible for reducing 
postoperative resource utilization, an understanding of the cause of these readmissions must first 
be established. Suggestions for future work include root cause analyses to determine the factors 
contributing to ED visits and readmissions in the postoperative setting for the comorbidities 
mentioned in this study. Additional work thereafter could include application of tactics targeted 
at these causes and an analysis of the impact of such interventions. 
 
LIMITATIONS 
Despite the advantages of using a large private payer database for studying postoperative 
resource utilization after cholecystectomy, there are several limitations to this approach. The 
major limitations relate to the use of claims data, namely that we must use ICD-9 diagnosis 
codes to determine patient comorbid conditions and that the study population is not nationally 
representative. The data source used in this study only included subscribers to a single private 
insurance provider and did not include the uninsured population. Using ICD-9 codes to 
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determine comorbidities can lead to under-representation of the conditions in the study 
population, though coding of chronic conditions tends to be much more complete at the time of 
hospitalization and/or surgical intervention. Although the comprehensive nature of patient 
utilization captured in claims data is helpful for elucidating 30-day postoperative resource 
utilization, it likely overestimates the use of resources associated with cholecystectomy, as the 
etiology of the visit or hospitalization could be another, unrelated source. 
Obesity is known to both correlate with and contribute to the pathophysiology of many of 
the conditions associated with increased utilization of resources in this study, such as 
hypertension, hyperlipidemia, GERD and hiatal hernia, diabetes mellitus, heart disease, sleep 
apnea, and heart failure45. The multivariate analyses we conducted allowed for the evaluation of 
each risk factor independently of the other but did not allow for the evaluation of the effects of 
obesity, a variable excluded from the study due to severe under-reporting of obesity codes. 
Martin et al’s Canadian study46 revealed that a diagnosis of obesity had a sensitivity of a mere 
7.75% in their database of 17,380 patients; similarly Januel et al47 show the scanty sensitivity of 
obesity coding in Switzerland (ranging from 29.4% in 1999 to 51.5% in 2003). These studies 
convey the extent to which obesity is under-reported in administrative databases. Therefore, it 
was not possible to determine the resultant effect of obesity on postoperative resource utilization 
in this study. In accordance with the ACA mandate that healthcare claims data be used 
extensively to assess resource utilization and quality of care starting in 201513, it is inevitable 
that large payer and other administrative databases will be increasingly used to evaluate 
healthcare systems in the near future. In order for authorities involved in all aspects of healthcare 
to draw accurate conclusions from these databases, more precise coding information regarding 
obesity needs to be included. 
Finally, Rao et al demonstrated that dialysis-dependent patients with end-stage renal 
disease had an increased risk of a number of postoperative complications after laparoscopic 
cholecystectomy which led to increased mean length of stay in the hospital48. Due to the low 
number of patients with renal failure in the study cohort, however, this condition was not 
included in the analysis. 
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CONCLUSIONS 
!
This study showed that certain comorbid conditions significantly increase utilization of 
postoperative resources in terms of ED visits and inpatient readmissions. In particular, heart 
failure, cirrhosis, and a history of MI / acute ischemic heart disease were not only significantly 
associated with increased ED utilization but also had the highest likelihood of inpatient 
readmission. Further investigation may identify the causality of these relationships and lead to 
the development of preventive strategies. Such an approach has the potential to not only decrease 
unnecessary visits, but also improve the quality of patient care and maintain provider profit 
margins in the face of decreasing reimbursements for surgical procedures. These factors should 
be considered in bundled reimbursement packages given their role in determining potential 
resource utilization in the postoperative setting. 
 
A report of this work has been previously published (Boehme et al, 2015)49. 
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FIGURES AND TABLES 
!
Figure 1: Profiles of health spending and coverage in eleven countries6.!
 Health spending, 2011  
 Per capita, USD % GDP Deductible 
United States $8,508 17.7% Yes, no limit 
Netherlands $5,099 11.9% $460 
France $4,118 11.6% No 
Germany $4,495 11.3% No 
Canada $4,522 11.2% No 
Switzerland $5,643 11.0% $319-2,655 
New Zealand $3,182 10.3% No 
Sweden $3,925 9.5% No 
United Kingdom $3,405 9.4% No 
Norway $5,669 9.3% No 
Australia $3,800 8.9% No 
!
Figure 2: Health insurance coverage for a core set of services, 20079. 
 
 
J.Boehme!
28 
 
Figure 3: The relationship between life expectancy and health spending per person11. 
 
 
Figure 4: The relationship between child mortality and health spending per person11. 
 
!
! !
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Table 1: Baseline patient characteristics. 
Variable n  % 
Sex   
Female 38,171 71.2 
Male 15,461 28.8 
Age mean ± SD (range) 48.7 ± 15.6 (16-99)  
Age group, years   
< 25 3015 5.6 
25 - < 35 8275 15.4 
35 - < 45 11,400 21.3 
45 - < 55 12,676 23.6 
55 - < 65 10,678 19.9 
65 - < 75 4,283 8.0 
75+ 3,305 6.2 
Region of country   
Northeast 9,715 18.1 
Midwest 8,906 16.6 
South 27,439 51.2 
West 7,528 14.0 
Unknown 44 0.1 
Type of surgery   
Laparoscopic 50,900 94.9 
Open 2,161 4.0 
Unknown/conversion* 571 1.1 
Surgery visit type   
Outpatient 34,285 63.9 
Inpatient 19,347 36.1 
*Indicates that both laparoscopic and open procedures were coded in claims database. 
 
Table 2: Prevalence of comorbidities in the study population. 
Comorbidity n % 
Hypertension 18,324 34.2 
Hyperlipidemia 16,436 30.7 
GERD / hiatal hernia 13,465 25.1 
Diabetes mellitus 7,354 13.7 
Angina / chronic IHD 4,065 7.6 
Sleep apnea 3,064 5.7 
Heart failure 1,217 2.3 
MI / acute IHD 1,136 2.1 
Hypertensive heart disease 1,061 2.0 
Cirrhosis of liver or bile ducts 283 0.5 
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Table 3: 30-day health care utilization. 
Visit Type Number of 
Visits 
Number of 
Patients 
% of Cohort 
ED visits 4,523 3,538 6.6 
Inpatient readmissions  4,103 7.7 
0 days  2,461 60.0 
1-2 days  677 16.5 
3-5 days  583 14.2 
6-10 days  214 5.2 
11+ days  168 4.1 
 
Table 4: ICD-9 codes and corresponding diagnoses for 30-day readmissions. 
ICD-9 Corresponding Diagnosis n % 
789.00 Abdominal pain; unspecified site 700 7.6 
786.50 Chest pain NOS* 223 2.4 
789.01 Abdominal pain; right upper quadrant 217 2.4 
997.4 Digestive system complications 212 2.3 
574.50 Choledocholithiasis NOS 205 2.2 
577.0 Acute pancreatitis 190 2.1 
574.10 Calculus of gallbladder with other cholecystitis; without 
mention of obstruction 
164 1.8 
576.8 Other specified disorders of the biliary tract 152 1.7 
789.07 Abdominal pain, generalized 146 1.6 
787.01 Nausea with vomiting 145 1.6 
*NOS: Not otherwise specified 
 
Table 5: Univariate analysis of 30-day resource utilization stratified by sex. 
 Female 
N=38,171 
Male 
N=15,461 
 
Chi Square 
 n % n % P value 
Visit to the ED 2,552 6.7 986 6.4 0.1925 
30-day readmission 2,579 6.8 1,524 9.9 <.0001 
 
Table 6: Univariate analysis of 30-day resource utilization stratified by comorbidity. 
Heart Failure 
 (+) N=1,217 (-) N=52,415 Chi Square 
 n % n % P value 
Visit to the ED 131 10.8 3,407 6.5 <.0001 
30-day readmission 348 28.6 3,755 7.2 <.0001 
Angina / Chronic IHD 
 (+) N=4,065 (-) N=49,567 Chi Square 
 n % n % P value 
Visit to the ED 344 8.5 3,194 6.4 <.0001 
30-day readmission 740 18.2 3,363 6.8 <.0001 
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GERD / Hiatal Hernia 
 (+) N=13,465 (-) N=40,167 Chi Square 
 n % n % P value 
Visit to the ED 1,009 7.5 2,529 6.3 <.0001 
30-day readmission 1,103 8.2 3,000 7.5 0.7087 
Myocardial Infarction / Acute IHD 
 (+) N=1,136 (-) N=52,496 Chi Square 
 n % n % P value 
Visit to the ED 104 9.2 3,434 6.5 0.0004 
30-day readmission 243 21.4 3,860 7.4 <.0001 
Sleep Apnea 
 (+) N=3,064 (-) N=50,568 Chi Square 
 n % n % P value 
Visit to the ED 249 8.1 3,289 6.5 0.0004 
30-day readmission 293 9.6 3,810 7.5 0.7843 
Diabetes Mellitus 
 (+) N=7,354 (-) N=46,278 Chi Square 
 n % n % P value 
Visit to the ED 547 7.4 2,991 6.5 0.0018 
30-day readmission 912 12.4 3,191 6.9 <.0001 
Hypertension 
 (+) N=18,324 (-) N=35,308 Chi Square 
 n % n % P value 
Visit to the ED 1,280 7.0 2,258 6.4 0.0090 
30-day readmission 1,986 10.8 2,117 6.0 <.0001 
Cirrhosis of the Liver or Bile Ducts 
 (+) N=283 (-) N=53,349 Chi Square 
 n % n % P value 
Visit to the ED 28 9.9 3,510 6.6 0.0251 
30-day readmission 43 15.2 4,060 7.6 0.1382 
Hyperlipidemia 
 (+) N=16,436 (-) N=37,196 Chi Square 
 n % n % P value 
Visit to the ED 1,040 6.3 2,498 6.7 0.0950 
30-day readmission 1,551 9.4 2,552 6.9 0.0001 
Hypertensive Heart Disease 
  (+) N=1,061  (-) N=52,571 Chi Square 
 n % n % P value 
Visit to the ED 79 7.4 3,459 6.6 0.2605 
30-day readmission 156 14.7 3,947 7.5 0.5003 
!
Table 7: Multivariable odds ratios for 30-day readmissions. 
Predictor Odds Ratio 95% Wald Confidence Limits 
Chi Square 
P-Value 
Female 0.885 0.823 0.950 0.0008 
Region (Reference: Midwest):     
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            Northeast 0.905 0.811 1.010 <.0001 
            South 0.885 0.809 0.969  
            West 0.969 0.862 1.090  
Age Group (Reference: 25-34)     
            <25 1.347 1.131 1.605 <.0001 
            35-44 0.993 0.872 1.130  
            45-54 1.061 0.935 1.204  
            55-64 1.287 1.131 1.465  
            65-74 2.003 1.730 2.317  
            75+ 4.277 3.717 4.922  
Baseline Comorbidities:     
Heart Failure 2.078 1.795 2.406 <.0001 
Cirrhosis of Liver or Bile 
Ducts 
1.640 1.164 2.312 0.0047 
MI / Acute IHD 1.463 1.236 1.733 <.0001 
Angina / Chronic IHD  1.300 1.162 1.454 <.0001 
Diabetes 1.293 1.184 1.413 <.0001 
Hypertensive Heart Disease 1.244 1.035 1.495 0.0201 
Hypertension 1.188 1.097 1.287 <.0001 
Hyperlipidemia 0.867 0.801 0.938 0.0004 
Predictors that were not statistically significant: GERD and sleep apnea. 
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APPENDICES 
!
Appendix 1: ICD-9 codes and CPT codes used to identify cholecystectomy procedures. 
ICD-9 
51.22 Cholecystectomy 
51.23 Laparoscopic cholecystectomy 
CPT 
47600 Cholecystectomy 
47610 Cholecystectomy with exploration of common duct 
47605 Cholecystectomy; with cholangiography 
47562 Laparoscopic cholecystectomy 
47563 Laparoscopic cholecystectomy with cholangiography 
47564 Laparoscopic cholecystectomy with exploration of common duct 
 
Appendix 2: Detailed univariate analysis of 30-day resource utilization stratified by sex. 
 Female 
N=38,171 
Male 
N=15,461 
 
Chi Square 
 n % n % P value 
Visit to the ED 2,552 6.7 986 6.4 0.1925 
Number of ED visits       
None 35,619 93.3 14,475 93.6  
1 visit 2,018 5.3 806 5.2  
2 visits 393 1.0 137 0.9  
3+ visits 141 0.4 43 0.3  
30-day readmission 2,579 6.8 1,524 9.9 <.0001 
Inpatient total LOS      
0 days 1,501 3.9 960 6.2  
1-2 days 469 1.2 208 1.3  
3-5 days 378 1.0 205 1.3  
6-10 days 132 0.3 82 0.5  
11+ days 99 0.3 69 0.4   
 
Appendix 3: Detailed univariate analysis of 30-day resource utilization stratified by 
comorbidity. 
Heart Failure 
 (+) N=1,217 (-) N=52,415 Chi Square 
 n % n % P value 
Visit to the ED 131 10.8 3,407 6.5 <.0001 
Number of ED visits       
None 1,086 89.2 49,008 93.5   
1 visit 92 7.6 2,732 5.2   
2 visits 22 1.8 508 1.0   
3+ visits 17 1.4 167 0.3   
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30-day readmission 348 28.6 3,755 7.2 <.0001 
Inpatient total LOS           
0 days 256 21.0 2,205 4.2   
1-2 days 34 2.8 643 1.2   
3-5 days 24 2.0 559 1.1   
6-10 days 12 1.0 202 0.4   
11+ days 22 1.8 146 0.3   
Angina / Chronic IHD 
 (+) N=4,065 (-) N=49,567 Chi Square 
 n % n % P value 
Visit to the ED 344 8.5 3,194 6.4 <.0001 
Number of ED visits       
None 3,721 91.5 46,373 93.6   
1 visit 265 6.5 2,559 5.2   
2 visits 58 1.4 472 1.0   
3+ visits 21 0.5 163 0.3   
30-day readmission 740 18.2 3,363 6.8 <.0001 
Inpatient total LOS           
0 days 540 13.3 1,921 3.9   
1-2 days 77 1.9 600 1.2   
3-5 days 58 1.4 525 1.1   
6-10 days 26 0.6 188 0.4   
11+ days 39 1.0 129 0.3   
GERD / Hiatal Hernia 
 (+) N=13,465 (-) N=40,167 Chi Square 
 n % n % P value 
Visit to the ED 1,009 7.5 2,529 6.3 <.0001 
Number of ED visits       
None 12,456 92.5 37,638 93.7   
1 visit 775 5.8 2,049 5.1   
2 visits 164 1.2 366 0.9   
3+ visits 70 0.5 114 0.3   
30-day readmission 1,103 8.2 3,000 7.5 0.7087 
Inpatient total LOS           
0 days 676 5.0 1,785 4.4   
1-2 days 169 1.3 508 1.3   
3-5 days 153 1.1 430 1.1   
6-10 days 61 0.5 153 0.4   
11+ days 44 0.3 124 0.3   
MI / Acute IHD 
 (+) N=1,136 (-) N=52,496 Chi Square 
 n % n % P value 
Visit to the ED 104 9.2 3,434 6.5 0.0004 
Number of ED visits       
None 1,032 90.8 49,062 93.5   
1 visit 80 7.0 2,744 5.2   
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2 visits 17 1.5 513 1.0   
3+ visits 7 0.6 177 0.3   
30-day readmission 243 21.4 3,860 7.4 <.0001 
Inpatient total LOS           
0 days 181 15.9 2,280 4.3   
1-2 days 22 1.9 655 1.2   
3-5 days 21 1.8 562 1.1   
6-10 days 10 0.9 204 0.4   
11+ days 9 0.8 159 0.3   
Sleep Apnea 
 (+) N=3,064 (-) N=50,568 Chi Square 
 n % n % P value 
Visit to the ED 249 8.1 3,289 6.5 0.0004 
Number of ED visits       
None 2,815 91.9 47,279 93.5   
1 visit 197 6.4 2,627 5.2   
2 visits 34 1.1 496 1.0   
3+ visits 18 0.6 166 0.3   
30-day readmission 293 9.6 3,810 7.5 0.7843 
Inpatient total LOS           
0 days 179 5.8 2,282 4.5   
1-2 days 53 1.7 624 1.2   
3-5 days 36 1.2 547 1.1   
6-10 days 13 0.4 201 0.4   
11+ days 12 0.4 156 0.3   
Diabetes Mellitus 
 (+) N=7,354 (-) N=46,278 Chi Square 
 n % n % P value 
Visit to the ED 547 7.4 2,991 6.5 0.0018 
Number of ED visits       
None 6,807 92.6 43,287 93.5  
1 visit 431 5.9 2,393 5.2  
2 visits 77 1.0 453 1.0  
3+ visits 39 0.5 145 0.3  
30-day readmission 912 12.4 3,191 6.9 <.0001 
Inpatient total LOS           
0 days 577 7.8 1,884 4.1  
1-2 days 130 1.8 547 1.2  
3-5 days 116 1.6 467 1.0  
6-10 days 47 0.6 167 0.4  
11+ days 42 0.6 126 0.3   
Hypertension 
 (+) N=18,324 (-) N=35,308 Chi Square 
 n % n % P value 
Visit to the ED 1,280 7.0 2,258 6.4 0.0090 
Number of ED visits       
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None 17,044 93.0 33,050 93.6  
1 visit 1,012 5.5 1,812 5.1  
2 visits 181 1.0 349 1.0  
3+ visits 87 0.5 97 0.3  
30-day readmission 1,986 10.8 2,117 6.0 <.0001 
Inpatient total LOS           
0 days 1,283 7.0 1,178 3.3  
1-2 days 413 2.3 413 1.2  
3-5 days 335 1.8 335 0.9  
6-10 days 117 0.6 117 0.3  
11+ days 74 0.4 74 0.2   
Cirrhosis of the Liver or Bile Ducts 
 (+) N=283 (-) N=53,349 Chi Square 
 n % n % P value 
Visit to the ED 28 9.9 3,510 6.6 0.0251 
Number of ED visits       
None 255 90.1 49,839 93.4   
1 visit 19 6.7 2,805 5.3   
2 visits 7 2.5 523 1.0   
3+ visits 2 0.7 182 0.3   
30-day readmission 43 15.2 4,060 7.6 0.1382 
Inpatient total LOS           
0 days 27 9.5 2,434 4.6   
1-2 days 3 1.1 674 1.3   
3-5 days 5 1.8 578 1.1   
6-10 days 5 1.8 209 0.4   
11+ days 3 1.1 165 0.3   
Hyperlipidemia 
 (+) N=16,436 (-) N=37,196 Chi Square 
 n % n % P value 
Visit to the ED 1,040 6.3 2,498 6.7 0.0950 
Number of ED visits       
None 15,396 93.7 34,698 93.3   
1 visit 836 5.1 1,988 5.3   
2 visits 150 0.9 380 1.0   
3+ visits 54 0.3 130 0.3   
30-day readmission 1,551 9.4 2,552 6.9 0.0001 
Inpatient total LOS           
0 days 1,001 6.1 1,460 3.9   
1-2 days 218 1.3 459 1.2   
3-5 days 193 1.2 390 1.0   
6-10 days 78 0.5 136 0.4   
11+ days 61 0.4 107 0.3   
Hypertensive Heart Disease 
  (+) N=1,061  (-) N=52,571 Chi Square 
 n % n % P value 
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Visit to the ED 79 7.4 3,459 6.6 0.2605 
Number of ED visits       
None 982 92.6 49,112 93.4   
1 visit 61 5.7 2,763 5.3   
2 visits 15 1.4 515 1.0   
3+ visits 3 0.3 181 0.3   
30-day readmission 156 14.7 3,947 7.5 0.5003 
Inpatient total LOS           
0 days 94 8.9 2,367 4.5   
1-2 days 22 2.1 655 1.2   
3-5 days 20 1.9 563 1.1   
6-10 days 10 0.9 204 0.4   
11+ days 10 0.9 158 0.3   
Appendix 4: Multivariable odds ratios for 30-day readmissions with same-day discharge. 
Predictor Odds Ratio 95% Wald Confidence Limits 
Chi Square 
P-Value 
Age Group (Reference: 25-34 
years)    <.0001 
<25 1.405 1.102 1.792  
35-44 1.012 0.843 1.216  
45-54 1.130 0.947 1.349  
55-64 1.420 1.188 1.698  
65-74 3.192 2.646 3.850  
75+ 7.772 6.498 9.297  
Baseline Comorbidities:     
Angina / Chronic IHD 1.363 1.197 1.553 <.0001 
Cirrhosis of the Liver or 
Bile Ducts 
1.634 1.066 2.504 0.0241 
Diabetes 1.226 1.099 1.368 0.0003 
Heart Failure 1.964 1.662 2.322 <.0001 
Hyperlipidemia 0.884 0.801 0.975 0.0138 
Hypertension 1.122 1.013 1.242 0.0269 
MI / Acute IHD 1.564 1.290 1.897 <.0001 
Predictors that were not significant: Sex, region, GERD, sleep apnea, hypertensive heart 
disease 
!
Appendix 5: Multivariable odds ratios for 30-day overnight readmissions. 
Predictor Odds Ratio 95% Wald Confidence Limits 
Chi Square 
P-Value 
Female 0.854 0.767 0.951 0.0040 
Region (Reference: Midwest):     
            Northeast 0.963 0.820 1.131 0.0056 
            South 0.819 0.715 0.937  
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            West 0.968 0.814 1.151  
Baseline Comorbidities:     
Angina / Chronic IHD 1.207 1.012 1.439 0.0360 
Diabetes 1.377 1.201 1.579 <.0001 
Heart Failure 1.874 1.475 2.381 <.0001 
Hyperlipidemia 0.863 0.766 0.973 0.0163 
Hypertension 1.271 1.131 1.428 <.0001 
Hypertensive Heart Disease 1.580 1.207 2.069 0.0009 
Predictors that were not statistically significant: Age, GERD, sleep apnea, acute IHD, and 
cirrhosis of the liver or bile ducts. 
 
